What is Lexicon Pharmaceuticals, Inc.'s current stock price?

Lexicon Pharmaceuticals, Inc. (LXRX) currently trades at USD 1.59. Track real-time price changes and historical performance on AllInvestView.

What sector is Lexicon Pharmaceuticals, Inc. in?

Lexicon Pharmaceuticals, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Lexicon Pharmaceuticals, Inc.

🧾 Earnings Recap – Q3 2025

Lexicon Pharmaceuticals reported strong progress in advancing its R&D pipeline during Q3 2025, with significant milestones reached across key therapeutic programs, despite ongoing challenges in the regulatory landscape.

Achieved Phase III readiness for pilavapadin, targeting diabetic peripheral neuropathic pain, and ongoing discussions with the FDA for next steps.
Completed IND-enabling studies for LX9851, entering a partnership with Novo Nordisk that may yield up to $30 million in milestone payments.
Active enrollment in the Phase III SONATA study for sotagliflozin, addressing both obstructive and non-obstructive hypertrophic cardiomyopathy subtypes.
Implemented an innovative virtual sales system aimed at transforming INPEFA into a profitable revenue stream by 2026.
Engaged in proactive discussions with the FDA regarding Zynquista, providing additional supporting data to address previous regulatory concerns.

View full recap page

Lexicon Pharmaceuticals, Inc. Analysis (LXRX)

United States Health Care Official Website Stock

Is Lexicon Pharmaceuticals, Inc. a good investment? Lexicon Pharmaceuticals, Inc. (LXRX) is currently trading at 1.59 USD. Market analysts have a consensus price target of 3.36 USD. This suggests a potential upside from current levels.

Earnings Schedule: Lexicon Pharmaceuticals, Inc. is expected to release its next earnings report on April 30, 2026. The market consensus estimate for Forward EPS is -0.21.

Investor FAQ

Does Lexicon Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Lexicon Pharmaceuticals, Inc.?

Lexicon Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 30, 2026. The company currently has a trailing EPS of -0.14.

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Split Date	Split Ratio to 1
May 21, 2015	0.140000

Split Date

Split Ratio to 1

May 21, 2015

0.140000

Lexicon Pharmaceuticals, Inc. LXRX Open Lexicon Pharmaceuticals, Inc. in new tab

Lexicon Pharmaceuticals, Inc.

Key Metrics

Growth

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features